Telix Pharmaceuticals

Telix Pharmaceuticals is a commercial-stage biopharmaceutical entity focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. (Incorporated in Australia)

The mission is to be the global leader in radiopharmaceuticals by combining therapeutic and diagnostic modalities for the benefit of patients, an innovative precision medicine concept generally referred to as “theranostics.” An extensive pipeline of theranostic radiopharmaceutical product candidates is maintained with a focus in urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma), and bone marrow conditioning.

The theranostic approach is intended to use imaging and therapy together to “see and treat” cancer and rare diseases, to both better inform treatment decisions and deliver personalized therapy for patients. The products are designed to deliver targeted radiation to cancer cells with precision via a systemic radioactive infusion in order to treat tumors regardless of their location in the body. This targeted radiation uses a radioactive isotope as a payload, which is attached to a targeting agent (such as a small molecule or antibody) with an affinity for targeted biomarkers on the surface of cancerous or diseased cells. Depending on the choice of radioisotope payload, the payload can be delivered as an imaging agent or as a therapy. The specificity of the targeting agent is designed to concentrate radiation at the tumor sites and limit off-target tissue exposure.

55 Flemington Road North Melbourne, Victoria, 3051, Australia

Christian Behrenbruch - Managing Director & Group Chief Executive Officer,

Dr David Cade - Group Chief Medical Officer,

James Stonecypher - Chief Development Officer.